Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HHAT | Q5VTY9 | 4/20 | 0.48 |
| ▸ | LHCGR | P22888 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499097 | 1.00 | HHAT (0.48) | HHATLHCGRNPSR1MAPK1KDM4E | |
| SCHEMBL5439863 | 1.00 | HHAT (0.48) | HHATLHCGRNPSR1MAPK1KDM4E | |
| Hydrochloric Acid SCHEMBL5239130 | 0.99 | HHAT (0.47) | HHATLHCGRNPSR1MAPK1KDM4E | |
| Bromide SCHEMBL4019730 | 0.99 | HHAT (0.47) | HHATLHCGRNPSR1MAPK1KDM4E | |
| SCHEMBL24419940 | 0.86 | HHAT (0.52) | HHATLHCGR | |
| SCHEMBL2307868 | 0.86 | HHAT (0.48) | HHATLHCGRNPSR1MAPK1DRD1 | |
| SCHEMBL4738266 | 0.86 | HHAT (0.48) | HHATLHCGRNPSR1MAPK1DRD1 | |
| SCHEMBL2916838 | 0.83 | HDAC8 (0.42) | NPSR1KDM4EDRD1 | |
| Sulfuric Acid SCHEMBL2306919 | 0.82 | HHAT (0.45) | HHATLHCGRDRD1 | |
| SCHEMBL5769463 | 0.79 | HHAT (0.38) | HHATLHCGRNPSR1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006042481-A1 | METHOD OF OBTAINING CLOPIDOGREL | ZENTIVA A.S. (CZ) | 2006-04-27 | — | — | WO | claimed |
| US-20060074242-A1 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | USV LIMITED (IN) | 2006-04-06 | — | — | US | claimed |
| US-20090187022-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS. | 2009-07-23 | — | — | US | disclosed |
| EP-2078025-A2 | PROCESS FOR THE SYNTHESIS OF CLOPIDOGREL AND NEW FORMS OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2009-07-15 | — | — | EP | disclosed |
| EP-1907397-A4 | METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN | HANMI PHARM IND CO LTD (KR) | 2009-05-27 | — | — | EP | disclosed |
| EP-1907397-A1 | METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2008-04-09 | — | — | EP | disclosed |
| WO-2008034912-A2 | PROCESS FOR THE SYNTHESIS OF CLOPIDOGREL AND NEW FORMS OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2008-03-27 | — | — | WO | disclosed |
| WO-2006137628-A1 | METHOD OF PREPARING CLOPIDOGREL AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006042481-A1 | METHOD OF OBTAINING CLOPIDOGREL | ZENTIVA A.S. (CZ) | 2006-04-27 | — | — | WO | disclosed |
| EP-1606231-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | Nadkarni, Sunil Sadanand (IN) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004074215-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | NADKARNI SUNIL SADANAND (IN) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074242-A1 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | SRR, P2RY11, CYP2C19 | HHAT 3926/4885LHCGR 2959/4885NPSR1 212/4885 |
| US-20090187022-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | NUDT1, CYP2C9, PFKP | HHAT 2285/4885LHCGR 1304/4885NPSR1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.